Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Pani

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
Health Policy OPEN|March 11, 2024
The evolving value assessment of cancer therapies: Results from a modified Delphi studyMyrto Lee, Hugo Larose, Martin Gräbeldinger, et al.
Medrxiv : the Preprint Server for Health Sciences|May 1, 2026
LIFETIME JEM-DERIVED OCCUPATIONAL EXPOSURE BURDEN AND ODDS OF PARKINSON'S DISEASE AND PARKINSONISM IN A MATCHED CASE-CONTROL STUDYFreeman Lewis, Stefano Renzetti, Natalie Goulett, et al.
The American Journal of Psychiatry|December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind TrialMaurizio Fava, Stephen Stahl, Luca Pani, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2017
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational studySalvatore Petta, Marco Marzioni, Pierluigi Russo, et al.
The Journal of Clinical Psychiatry|June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled TrialMaurizio Fava, Stephen M Stahl, Luca Pani, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's diseasePatrick Bradley, Ron Akehurst, Clive Ballard, et al.
International Journal of Environmental Research and Public Health|September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different PredictorsRaffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 3, 2014
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's diseaseDerek L G Hill, Adam J Schwarz, Maria Isaac, et al.
Molecular Psychiatry|December 15, 2021
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trialsLuca Sforzini, Courtney Worrell, Melisa Kose, et al.
Annals of Neurology|July 24, 2023
Cluster Headache Genomewide Association Study and Meta-Analysis Identifies Eight Loci and Implicates Smoking as Causal Risk FactorBendik S Winsvold, Aster V E Harder, Caroline Ran, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
Health Policy OPEN|March 11, 2024
The evolving value assessment of cancer therapies: Results from a modified Delphi studyMyrto Lee, Hugo Larose, Martin Gräbeldinger, et al.
Medrxiv : the Preprint Server for Health Sciences|May 1, 2026
LIFETIME JEM-DERIVED OCCUPATIONAL EXPOSURE BURDEN AND ODDS OF PARKINSON'S DISEASE AND PARKINSONISM IN A MATCHED CASE-CONTROL STUDYFreeman Lewis, Stefano Renzetti, Natalie Goulett, et al.
The American Journal of Psychiatry|December 22, 2021
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind TrialMaurizio Fava, Stephen Stahl, Luca Pani, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2017
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational studySalvatore Petta, Marco Marzioni, Pierluigi Russo, et al.
The Journal of Clinical Psychiatry|June 25, 2024
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled TrialMaurizio Fava, Stephen M Stahl, Luca Pani, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 23, 2014
Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's diseasePatrick Bradley, Ron Akehurst, Clive Ballard, et al.
International Journal of Environmental Research and Public Health|September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different PredictorsRaffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 3, 2014
Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's diseaseDerek L G Hill, Adam J Schwarz, Maria Isaac, et al.
Molecular Psychiatry|December 15, 2021
A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trialsLuca Sforzini, Courtney Worrell, Melisa Kose, et al.
Annals of Neurology|July 24, 2023
Cluster Headache Genomewide Association Study and Meta-Analysis Identifies Eight Loci and Implicates Smoking as Causal Risk FactorBendik S Winsvold, Aster V E Harder, Caroline Ran, et al.
Pageof 14